The company states: “Glaukos (GKOS) announced it has received European Union Medical Device Regulation certification for iStent infinite, along with several of its other leading micro-invasive glaucoma surgery technologies, including iStent inject W. Glaukos’ iStent trabecular micro-bypass stenting platform primarily involves the insertion of a micro-scale surgical devices designed to reduce intraocular pressure by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GKOS:
- Glaukos Positioned for Growth with Innovative Epioxa Therapy and First-Mover Advantage in Keratoconus Treatment
- Promising Outlook for Glaukos: Strategic Advancements and Market Growth Drive Buy Rating
- Glaukos’s Promising Long-Term Growth Driven by iDose and Strategic Developments
- Glaukos Stockholders Approve Key Proposals at Annual Meeting
- Cautious Outlook on Glaukos Amid Growth Opportunities and Market Access Challenges